Researcher awarded sits at the center of this dementia and brain health question.

Dr. Ryan S. Dhindsa, an assistant professor of pathology and immunology at Baylor College of Medicine and principal investigator at Texas Children’s Duncan Neurological Research Institute, has been awarded up to $2 million through the American Brain Foundation’s prestigious “Cure One, Cure Many” award in Neuroinflammation. This grant represents a significant investment in groundbreaking research exploring how viral infections may trigger or accelerate Alzheimer’s disease—a question that has intrigued researchers for years but remains largely unanswered.

The research project will examine genetic and health data from more than 1 million individuals to identify patterns linking viral exposures, immune responses, and Alzheimer’s development. Rather than focusing on a single aspect of the disease, Dhindsa’s team aims to answer three critical questions: which specific viruses might trigger Alzheimer’s pathology, why some people appear more vulnerable to viral-driven neurodegeneration than others, and how antiviral therapies or preventive vaccines might stop or slow the disease process. This multi-institutional effort, which includes co-investigators Dr. Caleb Lareau at Memorial Sloan Kettering Cancer Center and Dr. Artem Babaian at the University of Toronto, represents a departure from traditional Alzheimer’s research and opens the door to entirely new prevention and treatment strategies.

Who Is Dr. Ryan Dhindsa and Why Does His Research Matter?
How Do Viral Infections Connect to Alzheimer’s Disease Development?
What Are the Specific Research Goals and Project Scope?
Why Is This Award Significant for Alzheimer’s Prevention and Treatment?
What Challenges Exist in Linking Viruses to Alzheimer’s Risk?
How Will the Research Data From Over 1 Million Patients Be Leveraged?
What Could This Research Mean for Future Alzheimer’s Prevention and Treatment?
Conclusion

Who Is Dr. Ryan Dhindsa and Why Does His Research Matter?

Dr. Dhindsa holds dual positions at two leading institutions—Baylor College of Medicine and Texas Children’s Duncan neurological Research Institute—which places him at the intersection of clinical medicine and cutting-edge neuroscience research. His laboratory focuses on understanding how immune responses in the brain contribute to neurological disease, a field known as neuroinflammation.

Unlike researchers studying genetic mutations or protein accumulation alone, Dhindsa’s approach considers how external triggers like viral infections might activate the immune system in ways that damage brain cells over time. The significance of this award lies not just in the funding amount but in the recognition it represents. The American Brain Foundation’s “Cure One, Cure Many” grant is designed to support research that tackles fundamental mechanisms of neurological disease—work that could eventually benefit multiple conditions beyond Alzheimer’s. By understanding how viruses and immune responses interact in the brain, Dhindsa’s team may uncover principles applicable to other neurodegenerative diseases, making this a pivotal moment for dementia research broadly.

Who Is Dr. Ryan Dhindsa and Why Does His Research Matter?

How Do Viral Infections Connect to Alzheimer’s Disease Development?

The hypothesis that viral infections might contribute to Alzheimer’s is not new, but evidence has been fragmented and difficult to interpret. Some studies have suggested that individuals with a history of certain viral infections, including herpes simplex virus and cytomegalovirus, may have slightly elevated Alzheimer’s risk—but the mechanism remains unclear. Does the virus directly damage neurons? Does it trigger a prolonged inflammatory response that gradually harms brain tissue? Does it interact with genetic risk factors in specific ways? These are the questions Dhindsa’s research will address systematically.

However, simply finding a correlation between past viral exposure and Alzheimer’s diagnosis is not enough. A critical challenge is determining causation: did the virus cause the Alzheimer’s pathology, or did early Alzheimer’s-related immune dysfunction make the person more susceptible to severe viral infection? The project’s scale—analyzing data from over 1 million individuals—aims to tease apart these relationships by examining temporal patterns, genetic variations, and immune markers that distinguish people who develop Alzheimer’s after viral exposure from those who do not. This nuanced approach acknowledges that not all viral infections lead to Alzheimer’s, and not all people exposed to the same virus experience the same outcome.

What Are the Specific Research Goals and Project Scope?

The funded project has three interconnected research aims. First, the team will conduct a comprehensive search through the genetic and health data to identify which viral exposures are most strongly associated with Alzheimer’s development. This might reveal, for example, that a particular herpesvirus subtype or a specific combination of viral infections shows the strongest correlation with disease progression in certain demographic groups. Second, the research will investigate the biological mechanisms explaining why some individuals develop Alzheimer’s after viral infection while others remain cognitively healthy—this likely involves genetic factors that influence how the immune system responds to the viral trigger.

The third and perhaps most clinically relevant aim is to identify potential intervention points. If viral infections or the immune response they trigger are part of the Alzheimer’s pathway, then antiviral medications (like antivirals already used for herpes) might slow or prevent disease in certain patient groups. Alternatively, a vaccine strategy—potentially immunizing people at risk before they develop symptoms—could prevent the viral infection entirely or teach the immune system to respond more effectively without triggering damaging neuroinflammation. These translational possibilities transform what might seem like basic science into actionable prevention strategies.

What Are the Specific Research Goals and Project Scope?

Why Is This Award Significant for Alzheimer’s Prevention and Treatment?

Current Alzheimer’s treatment options remain limited. Approved medications like aducanumab and lecanemab target amyloid-beta, the protein that accumulates in the brains of Alzheimer’s patients, but they offer modest benefits and work best in early stages of disease. Prevention strategies are even more limited and typically involve lifestyle modifications—cognitive engagement, exercise, Mediterranean diet—without specific pharmaceutical interventions.

A prevention strategy based on identifying and treating or preventing viral infections would offer something fundamentally different: a potentially modifiable risk factor with clear medical interventions already available. The $2 million grant also signals that major research institutions and funding bodies view the viral hypothesis as sufficiently promising to warrant major investment. This validates the direction of the research and will likely attract additional funding and collaborations, accelerating the pace of discovery. For patients and families dealing with Alzheimer’s, this research represents hope for preventive approaches that might eventually reduce disease incidence, particularly in populations showing the strongest viral-Alzheimer’s associations.

What Challenges Exist in Linking Viruses to Alzheimer’s Risk?

One major challenge is the difficulty of establishing clear causation in epidemiological research. Millions of people have been exposed to common viruses like herpes simplex, yet only a fraction develop Alzheimer’s. This means that viral infection alone is not sufficient to cause disease; it likely requires interaction with genetic predisposition, aging, other environmental factors, or previous immune system dysfunction. Disentangling these contributions requires sophisticated statistical methods and large datasets—which is why the 1 million-person cohort is essential. However, even with this large scale, proving causation rather than correlation remains scientifically challenging.

Another limitation is the reliance on historical health data. Researchers cannot ethically infect people with viruses to see if Alzheimer’s develops, so they must work with existing medical records and biological samples collected for other purposes. These datasets may have gaps in viral exposure history—people may have had asymptomatic infections that were never documented or forgotten infections from decades past. Additionally, viruses themselves evolve, and historical exposure to a particular viral strain may not predict risk from current variants. The research team will need to account for these limitations as they design their analytical approach.

What Challenges Exist in Linking Viruses to Alzheimer's Risk?

How Will the Research Data From Over 1 Million Patients Be Leveraged?

The project will integrate multiple types of data from participating individuals: genetic information identifying variations that influence immune function, medical records documenting viral infections and cognitive outcomes, and potentially biomarker data from blood or spinal fluid samples showing immune activation patterns. This integrated approach allows researchers to ask sophisticated questions that would be impossible with a single data type.

For example, they could ask: “Among people with a particular immune-related genetic variant, does prior herpesvirus infection increase Alzheimer’s risk, and is this effect mediated by elevated inflammatory markers?” A practical example of how this might work: if the research identifies that people carrying a specific genetic variant who were also infected with cytomegalovirus show a fivefold higher Alzheimer’s risk compared to unexposed people with the same variant, this could justify developing a prevention trial targeting that subgroup. Rather than proposing a prevention strategy for all older adults, researchers could identify a high-risk population where the benefit of antiviral therapy or vaccination would likely be substantial. This personalized medicine approach represents the future of Alzheimer’s prevention.

What Could This Research Mean for Future Alzheimer’s Prevention and Treatment?

If this research succeeds in identifying viral contributors to Alzheimer’s and establishing their mechanistic role, the implications could be transformative. Unlike current treatments that primarily slow cognitive decline in symptomatic patients, a prevention strategy could theoretically prevent disease from developing in the first place. Imagine a future where individuals are screened for both Alzheimer’s genetic risk factors and markers of susceptibility to virus-driven neuroinflammation, then offered targeted antiviral therapy or a preventive vaccine before cognitive symptoms appear.

This shifts the paradigm from treating disease to preventing it entirely. Looking forward, the insights from Dhindsa’s research could also inform strategies for protecting the brain during or after viral infections—a consideration that may become increasingly important as new infectious diseases emerge. The research team’s work with co-investigators at world-class cancer and viral research centers (Memorial Sloan Kettering and University of Toronto) suggests that discoveries here might have applications beyond Alzheimer’s, potentially informing prevention strategies for other neuroinflammatory conditions. The next few years of this funded research will likely reshape how researchers and clinicians think about infection, immunity, and neurodegeneration.

Conclusion

Dr. Ryan Dhindsa’s $2 million grant from the American Brain Foundation represents a significant investment in answering a fundamental question about Alzheimer’s disease: do viral infections play a role in triggering or accelerating cognitive decline, and if so, can we prevent this through antiviral interventions? By analyzing genetic and health data from over 1 million individuals across three leading research institutions, the project aims to move beyond correlation to establish mechanistic links between specific viral exposures and Alzheimer’s pathology. This research has the potential to identify entirely new prevention strategies, shifting the focus from treating symptomatic disease to preventing it in the first place.

For people concerned about Alzheimer’s risk or those with family history of dementia, this research offers a reminder that disease prevention often involves understanding modifiable risk factors. While results from this multi-year project are still years away, the work underway at Texas Children’s and partner institutions represents the kind of fundamental science that eventually translates into new treatments and preventive strategies. Staying informed about research directions like this one helps patients, families, and healthcare providers understand the future landscape of dementia care and the evolving science of prevention.